My hands shook as I texted my husband. I felt unmoored in my body, as if I’d awoken in a different house than the one where I ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The rash associated with shingles usually crusts over within seven to 10 days for people with a healthy immune system and ...

While red and itchy like other rashes, the shingles rash is otherwise very distinct. Vesicles (fluid-filled sacs) are ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Specifically, Shields is working to encourage others to embrace aging and the increased risk of shingles for people over 50 .

NanoViricides, Inc. (NYSE American.:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for ... on Thursday ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...